{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:32:10Z","timestamp":1765297930992,"version":"3.46.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Blue Cross Blue Shield of Michigan and Blue Care Network"},{"name":"BCBSM Value Partnerships"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The 2024 American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology practice guidelines recommend early salvage radiation therapy (RT) for biochemical recurrence after radical prostatectomy and androgen deprivation therapy for high-risk features. Increasingly, men with high-risk disease are undergoing radical prostatectomy. We therefore characterized contemporary RT and androgen deprivation therapy practices within the Michigan Radiation Oncology Quality Consortium and Michigan Urological Surgery Improvement Collaborative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients receiving postprostatectomy RT from June 9, 2020, to June 9, 2024, were eligible. Prospectively collected data\u00a0included surgical pathology, RT, and androgen deprivation therapy details. RT was adjuvant (pre-RT prostate-specific antigen [PSA] &amp;lt;0.1\u2009ng\/mL), consolidative (persistent PSA \u22650.1), or salvage (all others). Multivariable analyses evaluated associations between clinicopathologic features and androgen deprivation therapy use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 345 patients across 26 centers, 56% had at least 1 high-risk feature: pT3b\/T4 (24%), pN1 (6%), grade group 4\/5 (30%), pre-RT PSA greater than 0.5\u2009ng\/mL (27%). RT was adjuvant (10%), consolidative (28%), or salvage (62%), initiated at median PSA of 0.07 ng\/mL (interquartile range [IQR] = 0.03-0.09 ng\/mL), 0.5 ng\/mL (IQR = 0.3-1.5 ng\/mL), and 0.3\u2009ng\/mL (IQR = 0.2-0.5 ng\/mL), respectively. Median time to RT was 8, 6, and 29\u2009months. A minority were recommended 24\u2009months of androgen deprivation therapy (17%), and very few were recommended intensification with AR-pathway inhibitors (5%). On multivariate analysis, androgen deprivation therapy was associated with pT3b\/T4 (odds ratio [OR]\u2009=\u20092.77, 95% confidence interval [CI] = 1.34 to 5.93), pN1 (OR\u2009=\u20096.22, 95% CI = 1.35 to 47.57), grade group 4\/5 (OR\u2009=\u20092.87, 95% CI = 1.51 to 5.56), and pre-RT PSA more than 0.5 (OR\u2009=\u20092.11, 95% CI = 1.17 to 3.91).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within the Michigan Radiation Oncology Quality Consortium, more than half who received postprostatectomy RT had high-risk features; nearly 30% required consolidation for persistently positive PSA. Androgen deprivation therapy was associated with high-risk features, but few received androgen deprivation therapy prolongation or intensification. Studies are needed to personalize androgen deprivation therapy, especially for those with persistent PSA, who are frequently treated yet underrepresented in trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jncics\/pkaf112","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:07:51Z","timestamp":1763039271000},"source":"Crossref","is-referenced-by-count":0,"title":["Postprostatectomy prostate cancer treated with radiation therapy: adverse features and androgen deprivation therapy use in a statewide consortium"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5449-8348","authenticated-orcid":false,"given":"Samuel N","family":"Regan","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-7669","authenticated-orcid":false,"given":"Michael","family":"Dykstra","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Mislmani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, West Michigan Cancer Center , Kalamazoo, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Zaki","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Covenant Healthcare , Saginaw, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Henry Ford Providence Hospital , Novi, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Kendrick","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9718-1781","authenticated-orcid":false,"given":"Steven","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Karmanos Cancer Institute , Detroit, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9849","authenticated-orcid":false,"given":"Melissa","family":"Mietzel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tudor","family":"Borza","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Department of Urology, Wayne State University School of Medicine , Detroit, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Heimburger","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Munson Healthcare , Traverse City, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-0603","authenticated-orcid":false,"given":"Todd","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Schipper","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]},{"name":"Department of Biostatistics, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-5978","authenticated-orcid":false,"given":"William C","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-3758","authenticated-orcid":false,"given":"Robert T","family":"Dess","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"2025120911292666100_pkaf112-B1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2025120911292666100_pkaf112-B2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2025120911292666100_pkaf112-B3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/JU.0000000000003890","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"2025120911292666100_pkaf112-B4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"2025120911292666100_pkaf112-B5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025120911292666100_pkaf112-B6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025120911292666100_pkaf112-B7","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"key":"2025120911292666100_pkaf112-B8","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025120911292666100_pkaf112-B9","doi-asserted-by":"publisher","first-page":"e175230","DOI":"10.1001\/jamaoncol.2017.5230","article-title":"Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features","volume":"4","author":"Hwang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025120911292666100_pkaf112-B10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2024.02.024","article-title":"More than words: defining adjuvant, consolidative, and salvage treatment after radical prostatectomy","volume":"86","author":"Lane","year":"2024","journal-title":"Eur Urol"},{"key":"2025120911292666100_pkaf112-B11","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"2025120911292666100_pkaf112-B12","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025120911292666100_pkaf112-B13","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"2025120911292666100_pkaf112-B14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025120911292666100_pkaf112-B15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"2025120911292666100_pkaf112-B16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.eururo.2025.05.013","article-title":"Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for nonmetastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data","volume":"88","author":"Burdett","year":"2025","journal-title":"Eur Urol"},{"key":"2025120911292666100_pkaf112-B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.06.009","article-title":"Radiotherapy- versus surgery-based treatment strategy in high-risk prostate cancer","author":"Roy","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2025120911292666100_pkaf112-B18","doi-asserted-by":"publisher","first-page":"e70624","DOI":"10.1002\/cam4.70624","article-title":"Utilization of radical prostatectomy versus radiation therapy for gleason grade group 5 prostate cancer before and after USPSTF grade D recommendation against prostate-specific antigen screening in 2012","volume":"14","author":"McGinnis","year":"2025","journal-title":"Cancer Med"},{"key":"2025120911292666100_pkaf112-B19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"2025120911292666100_pkaf112-B20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ijrobp.2025.07.1416","article-title":"Long-term results of NRG\/RTOG 9601, a randomized trial of radiation with or without antiandrogens in patients receiving salvage prostate bed radiation therapy postprostatectomy","volume":"123","author":"Lukka","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025120911292666100_pkaf112-B21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025120911292666100_pkaf112-B22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djaf012","article-title":"Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study","volume":"117","author":"Scilipoti","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2025120911292666100_pkaf112-B23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/jamaoncol.2025.0110","article-title":"Persistent prostate-specific antigen following radical prostatectomy for prostate cancer and mortality risk","volume":"11","author":"Tilki","year":"2025","journal-title":"JAMA Oncol"},{"key":"2025120911292666100_pkaf112-B24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1200\/JCO.2024.42.4_suppl.131","article-title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: initial results from RTOG 3506 (STEEL)","volume":"42","author":"Posadas","year":"2024","journal-title":"J Clin Oncol"},{"year":"2025","author":"NRG Oncology","key":"2025120911292666100_pkaf112-B25"},{"key":"2025120911292666100_pkaf112-B26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102453","article-title":"The significance of prostate specific antigen persistence in prostate cancer risk groups on long-term oncological outcomes","volume":"13","author":"Milonas","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025120911292666100_pkaf112-B27","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"2025120911292666100_pkaf112-B28","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","article-title":"European association of urology biochemical recurrence risk classification as a decision tool for salvage radiotherapy-a multicenter study","volume":"85","author":"Preisser","year":"2024","journal-title":"Eur Urol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkaf112\/65357533\/pkaf112.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/6\/pkaf112\/65357533\/pkaf112.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/9\/6\/pkaf112\/65357533\/pkaf112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:29:35Z","timestamp":1765297775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkaf112\/8325308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkaf112","relation":{},"ISSN":["2515-5091"],"issn-type":[{"type":"electronic","value":"2515-5091"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,3]]},"article-number":"pkaf112"}}